RxDoctor Payments Data

Sai Gandham, MD

Ophthalmology · Slingerlands, NYNPI 1922007038

Payments from drug & device makers

$2,506in general payments, 2019–2025

Across 51 payments — averaging $49.13 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • Alcon$449
  • Sight Sciences, Inc.$281
  • Aerie Pharmaceuticals, Inc.$146
  • Tarsus Pharmaceuticals, Inc.$128
  • Amgen$115
  • plus $166 from 4 others

What the payments were for

  • Food & beverage$2,46698%
  • Education$402%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,506 in reported general payments places this provider in the 60th percentile of 1,587 ophthalmology providers in New York.

See all ophthalmology providers in New York

Medicare billing

Part B allowed, 2024
$93,933
Medicare patients
310
Services billed
1,225

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
LumiganBimatoprost167$112,075
RocklatanNetarsudil Mesylat/Latanoprost87$61,950
CombiganBrimonidine Tartrate/Timolol93$39,815
RhopressaNetarsudil Mesylate36$28,648
Alphagan PBrimonidine Tartrate44$23,458
VyzultaLatanoprostene Bunod27$21,415
Travoprost78$18,002
Timolol Maleate444$16,237
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol89$15,892
SimbrinzaBrinzolamide/Brimonidine Tart30$12,538
Brimonidine Tartrate248$9,634
Latanoprost582$9,536
Methazolamide29$8,034
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat432$7,566
Brinzolamide22$5,946

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLumigan, Combigan, Alphagan P$1,221$175,348304 claims
Aerie Pharmaceuticals, Inc.Rocklatan, Rhopressa$146$90,597123 claims
Bausch & Lomb Americas Inc.Vyzulta$75$21,41527 claims
AlconSimbrinza$449$12,53830 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 1,587 ophthalmology providers in New York.

Other ophthalmology in Slingerlands

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →